CERTAIN: CIMZIA in Rheumatoid Arthritis, final version 29-Oct-2007

• Research type

  Research Study

• Full title

  A Phase IIIB Multicenter, double-blind randomised, placebo-controlled parallel group 52-week study to evaluate safety and efficacy of the PEGylated anti- TNFá Fab' fragment, certolizumab pegol, administered concomitantly with stable-dose DMARDs in patients with moderate to low disease activity rheumatoid arthritis

• Contact name

  Paul Emery

• Contact email

  p.emery@leeds.ac.uk

• Sponsor organisation

  UCB Pharma S.A.

• Eudract number

  2007-000828-40

• ISRCTN Number

  NA

• Research summary

  Research Summary not published at request of reseacher

• REC name

  Yorkshire & The Humber - Leeds East Research Ethics Committee

• REC reference

  08/H1306/12

• Date of REC Opinion

  5 Feb 2009

• REC opinion

  Further Information Favourable Opinion